Lutein Antioxidant Supplement Trial (LAST): The most requested nutrient study at the Biosyntrx booth - ASCRS 2004
Friday, May 07, 2004
The Veterans LAST study (Lutein Antioxidant Supplementation Trial): Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration.
Methods: The study was a prospective, 12-month, randomized, double-masked, placebo-controlled trial conducted at an urban Midwestern Veterans Administration Hospital. Ninety patients with atrophic ARMD were referred by ophthalmologists at two Chicago-area veterans medical facilities. Patients in Group 1 received 10 mg of lutein (L): Group 2 received 10 mg of lutein plus an antioxidant/vitamin/mineral broad spectrum supplementation formula (L/A); and Group 3 received a placebo (P) over a 12 month period.
Clinical references available in the Biosyntrx office.